Article
Immunology
Xuesong Xu, Yi Hong, Erjing Chen, Yaping Wang, Biao Ma, Jiali Li, Wei Su, Yuxin Zhou, Mingzhou Zhang
Summary: This study discusses the inhibitory abilities of antibodies induced by primary and booster vaccines against different strains of SARS-CoV-2. The results show that homologous inactivated vaccines have the strongest inhibitory effects on the wild-type strain, but exhibit resistance against B.1.351, B.1.617.2, and B.1.1.529 mutants. Heterologous booster vaccination can significantly restore humoral immune responses and generate stronger antibody responses against various mutant strains.
Article
Public, Environmental & Occupational Health
Nathella Pavan Kumar, V. V. Banurekha, C. P. Girish Kumar, Arul Nancy, Chandrasekaran Padmapriyadarsini, Sakila Shankar, Luke Elizabeth Hanna, Manoj Murhekar, K. R. Uma Devi, Subash Babu
Summary: Covaxin induces a persistent and enhanced immune response against SARS-CoV-2 variants, with antibody levels remaining high up to 12 months after vaccination.
JOURNAL OF TRAVEL MEDICINE
(2022)
Article
Immunology
Hu Li, Shiyin Li, Pan Xu, Xiaohao Wang, Huan Deng, Yu Lei, Shan Zhong
Summary: This study evaluated the neutralizing antibody response after COVID-19 vaccination in hospitalized patients with liver dysfunction. It was found that patients with liver dysfunction had significantly lower levels of neutralizing antibodies compared to healthy controls, and factors such as male sex, severe liver injury, and chronic liver diseases were associated with poor antibody responses.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Virology
Sally Mahmoud, Subhashini Ganesan, Nawal Al Kaabi, Shivaraj Naik, Santosh Elavalli, Prem Gopinath, Alaa Mousa Ali, Lara Bazzi, Katherine Warren, Walid Abbas Zaher, Farida Al Hosani
Summary: This study compares the difference in neutralizing antibody titers against variants of concern of SARS-CoV-2 between primary doses and booster doses of the inactivated BBIBP-CorV vaccine. The results show that the booster dose provides better protection against the variants of concern.
JOURNAL OF CLINICAL VIROLOGY
(2022)
Article
Immunology
Liqing Chen, Xiaoxiao Qi, Dan Liang, Guiqi Li, Xiaofang Peng, Xiaohui Li, Bixia Ke, Huanying Zheng, Zhongqiu Liu, Changwen Ke, Guochao Liao, Liang Liu, Qian Feng
Summary: This study provides valuable information for the ongoing development of recombinant protein-based SARS-CoV-2 vaccines and serves as a basis for booster vaccinations to prevent reinfection with SARS-CoV-2 variants.
Article
Immunology
Alireza Abdollahi, Yeganeh Afsharyzad, Atefeh Vaezi, Alipasha Meysamie
Summary: This study examined the necessity of booster doses of COVID-19 vaccination. The results showed that individuals who received three doses of the vaccine had higher levels of antibodies, indicating that a booster dose enhances the antibody response.
Article
Microbiology
Haiying Zhang, Yuyuan Jia, Ying Ji, Xu Cong, Yan Liu, Ruifeng Yang, Xiangsha Kong, Yijun Shi, Ling Zhu, Zhenyu Wang, Wei Wang, Ran Fei, Feng Liu, Fengmin Lu, Hongsong Chen, Huiying Rao
Summary: This study evaluated the level and persistence of neutralizing antibodies (NAbs) induced by two inactivated COVID-19 vaccines in China. The results showed that the highest NAb positivity rate was observed in the first and second month after the second vaccine dose, and gradually declined over time. With a 21-day interval between doses, NAb levels persisted for only 6 months after the second dose. Age affected NAb levels, but sex did not.
FRONTIERS IN MICROBIOLOGY
(2022)
Article
Public, Environmental & Occupational Health
Gururaj Rao Deshpande, Pragya D. Yadav, Priya Abraham, Dimpal A. Nyayanit, Gajanan N. Sapkal, Anita M. Shete, Nivedita Gupta, Krishna Mohan Vadrevu, Raches Ella, Samiran Panda, Balram Bhargava
Summary: The neutralizing antibody responses significantly increased after the third dose of BBV152/Covaxin against B.1 (19.11-fold), Delta (16.51-fold), Beta (14.70-fold), and Omicron (18.53-fold) Variants of concern, compared to the two-dose vaccine, providing assurance of a protective immune response in recipients.
JOURNAL OF TRAVEL MEDICINE
(2022)
Article
Immunology
Katharine H. D. Crawford, Adam S. Dingens, Rachel Eguia, Caitlin R. Wolf, Naomi Wilcox, Jennifer K. Logue, Kiel Shuey, Amanda M. Casto, Brooke Fiala, Samuel Wrenn, Deleah Pettie, Neil P. King, Alexander L. Greninger, Helen Y. Chu, Jesse D. Bloom
Summary: Antibody levels, including neutralizing antibodies, decline after SARS-CoV-2 infection, with a 4-fold average decrease in titers from 1 to 4 months after symptom onset. This decline is accompanied by a decrease in total antibodies capable of binding the viral spike protein. Further studies are needed to determine the long-term durability of immunity to SARS-CoV-2, including examination of long-lived B cells and antibody titers over extended periods.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Letter
Immunology
Taweewun Hunsawong, Stefan Fernandez, Rome Buathong, Naretrit Khadthasrima, Kamonthip Rungrojchareonkit, Jindarat Lohachanakul, Rungarun Suthangkornkul, Kedsara Tayong, Angkana T. Huang, Chonticha Klungthong, Piyawan Chinnawirotpisan, Yongyuth Poolpanichupatam, Anthony R. Jones, Eric D. Lombardini, Supaporn Wacharapluesadee, Opass Putcharoen
Summary: In vitro testing of serum samples from CoronaVac vaccine recipients showed that neutralizing antibodies provided short-term protection against the original virus strain and limited protection against variants of concern. These findings support the use of vaccine boosters, particularly in regions where variants of concern are circulating.
EMERGING INFECTIOUS DISEASES
(2021)
Article
Immunology
Yu-An Kung, Sheng-Yu Huang, Chung-Guei Huang, Kuan-Ting Liu, Peng-Nien Huang, Kar-Yee Yu, Shu-Li Yang, Chia-Pei Chen, Ching-Yun Cheng, Ing-Kit Lee, Shu-Min Lin, Han-Pin Chang, Yueh-Te Lin, Yen-Chin Liu, Guang-Wu Chen, Shin-Ru Shih
Summary: The importance of an international standard for SARS-CoV-2 neutralizing antibody titer detection has been highlighted by the World Health Organization. In this study, we calibrated neutralizing antibody titers in response to COVID-19 vaccination using the international standard and analyzed the association between different factors and neutralizing antibodies. The findings have significant implications for vaccine development and the implementation of non-inferiority trials.
MICROBES AND INFECTION
(2023)
Article
Microbiology
Yu-Ching Dai, Yen-Chia Lin, Lauren L. Ching, Jih-Jin Tsai, Kyle Ishikawa, Wen-Yang Tsai, John J. Chen, Vivek R. Nerurkar, Wei-Kung Wang
Summary: Despite improved understanding of SARS-CoV-2 biology, the evolutionary trajectory of the virus remains uncertain, and the concern of future antigenically distinct variants persists. Current recommendations for COVID-19 booster dose are based on neutralization capacity, effectiveness against variants of concern, and other host factors. Our study investigated neutralization antibody titers against variants among COVID-19-naive participants receiving Moderna or Pfizer vaccines, and found that the time it took for neutralization titers to decline to a reference level of protection was longer in the Moderna group than in the Pfizer group, supporting the use of neutralization titers and half-life information to determine the optimal time for booster vaccination. Our study provides a framework to determine the individualized timing of booster dose against variants with high morbidity and mortality.
MICROBIOLOGY SPECTRUM
(2023)
Article
Immunology
Mustafa Genco Erdem, Ozge Unlu, Suleyman Buber, Mehmet Demirci, Bekir Sami Kocazeybek
Summary: This study aimed to determine the levels of anti-S-RBD antibodies and surrogate neutralizing antibodies after BNT162b2 vaccination, and found that prior SARS-CoV-2 infection and the third vaccine dose led to a slower decrease in antibody levels.
Article
Immunology
Yuting Liao, Yingping Chen, Bo Chen, Zhenzhen Liang, Xiaosong Hu, Bo Xing, Juan Yang, Qianhui Zheng, Qianhui Hua, Chuanfu Yan, Huakun Lv
Summary: The study demonstrates that heterologous boosting with ZF2001 is safe and immunogenic. There was no significant correlation between the strength of immune response after the third dose and the original vaccination interval among participants aged 18 and above. Additionally, older adults showed weaker immune responses to the vaccine compared to younger adults.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Yufei Wu, Ping Huang, Mingjie Xu, Qianqian Zhao, Yihui Xu, Shuyi Han, Huanjie Li, Yunshan Wang
Summary: Monitoring the dynamic change in neutralizing antibodies is necessary after COVID-19 vaccination. The rate of reduction of SARS-CoV-2 neutralizing antibody levels gradually showed after booster doses. CD25+T cell expression was significantly higher in the 18-35 age group. Booster vaccination in older adults and regular testing of neutralizing antibodies are recommended if the antibody level falls below 30% inhibition rate.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Gastroenterology & Hepatology
Jingwen Ai, Jitao Wang, Dengxiang Liu, Huiling Xiang, Ying Guo, Jiaojian Lv, Qiran Zhang, Jinlong Li, Xiaochong Zhang, Qianqian Li, Jing Liang, Xiaoqing Guo, Yinong Feng, Luxiang Liu, Xuying Zhang, Wei Qin, Xiaodong Wang, Wei Rao, Qun Zhang, Qiuju Tian, Yanliang Zhang, Faren Xie, Shujun Jiang, Yan Yan, Yuanwang Qiu, Hangyuan Wu, Zhiyun Hou, Nina Zhang, Aiguo Zhang, Jiansong Ji, Jie Yang, Jiansheng Huang, Zhongwei Zhao, Ye Gu, Li Bian, Zhen Zhang, Shengqiang Zou, Hailei Ji, Guohong Ge, Xiufang Du, Aifang Hou, Ying Zhu, Qingwei Cong, Juan Xu, Hongmei Zu, Yun Wang, Zhaolan Yan, Xiaosong Yan, Yangzhen BianBa, Qu Ci, Liting Zhang, Shiying Yang, Xiaoqin Gao, Li Zhong, Song He, Chuan Liu, Yifei Huang, Yanna Liu, Dan Xu, Qingliang Zhu, Xinxin Xu, Muhan Lv, Wenhong Zhang, Xiaolong Qi
Summary: This study assessed the safety and immunogenicity of inactivated whole-virion SARS-CoV-2 vaccines in patients with chronic liver diseases (CLD). The results showed that the vaccines were safe in CLD patients, but they had lower immunologic response compared to healthy individuals.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Cell Biology
Jingwen Ai, Jingxin Guo, Haocheng Zhang, Yi Zhang, Haochen Yang, Ke Lin, Jieyu Song, Zhangfan Fu, Mingxiang Fan, Qiran Zhang, Hongyu Wang, Yuanhan Zhao, Zhangyufan He, An Cui, Yang Zhou, Jing Wu, Mingzhe Zhou, Guanmin Yuan, Boxi Kang, Ning Zhao, Yuanyuan Xu, Mengqi Zhu, Youhong Wang, Zemin Zhang, Ning Jiang, Chao Qiu, Chenqi Xu, Wenhong Zhang
Summary: The study reveals the cellular mechanisms of booster-induced memory/adaptive humoral immunity. The heterologous booster can induce a faster and more robust plasmablast response, attributed to the recall of memory B cells and the activation of B cells. Expanded B cell clones can persist for months after booster dose vaccination.
